INTRODUCTION
instrument F100 (Sumitomo Heavy Industries, Ltd., Tokyo, Japan) and a cyclotron CYPRIS (Sumitomo Heavy Industries, Ltd.) in our institution. All patients were examined with PET/CT scanner (Aquiduo, Toshiba Medical Systems Corporation, Tochigi, Japan) 1 hour after FDG injection (3.7 MBq/kg). They were imaged from the top of the head to the middle of thigh. The attenuation -corrected PET image, non-attenuation-corrected PET image and CT image were reviewed, and the attenuation-corrected PET and CT image were co-registered using AquariusNET viewer (TeraRecon, Inc.). Eleven of the 20 patients underwent PET/CT prior to therapy. Three of these eleven patients also underwent follow-up PET/CT after operation or imatinib therapy. Nine of the 20 patients underwent PET/CT only after operation. Three of these nine patients had recurrent GIST. Of the eleven patients who underwent PET/CT prior to therapy, the primary tumor was located in the stomach in six patients, in the duodenum in two, and the small intestine in three.
The risk category was determined pathologically by tumor size and the number of mitotic cells (Table 1) (3) .
RESULTS
Tumor size, primary site, maximum standardized uptake value (SUVmax), and risk category of 20 patients who underwent PET/CT are presented in Table 2 . All eleven lesions were FDG-positive upon pre-treatment PET/CT (SUVmax 2.2-15.7, (Fig. 1) . All recurrent tumors showed high FDG uptake except for one case. The recurrent tumor of this case, confirmed high-risk at initial diagnosis, showed relatively low uptake (SUVmax 2.5). Six of the nine patients who underwent PET/CT only after operation had no abnormal FDG uptake on PET/CT.
CASE 1
A 72 -year -old woman had a mass behind the stomach, which measured 5.0! 3.5 cm, and showed mild FDG uptake with an SUVmax of 3.0 on PET/ CT (Fig. 2) . The abdominal mass was resected and 
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confirmed pathologically as GIST of the stomach, and categorized as low risk. No recurrence and metastasis were detected on follow-up PET/CT performed 3.5 months after the operation.
CASE 2
A 50-year-old man had an abdominal mass near the pancreatic body, which showed intense FDG uptake (SUVmax 8.0) (Fig. 3a) . Tumor with ulcer formation was detected in the horizontal part of the duodenum at endoscopy. For biopsy, the mass was confirmed pathologically as GIST of the duodenum and categorized as high risk. Systemic chemotherapy with imatinib mesylate was started as neoadjuvant therapy. Follow-up PET/CT was performed 4 months after chemotherapy showed a reduction in tumor size and decreased FDG uptake (SUVmax 5.0) (Fig. 3b) . However, follow-up PET/CT at 10 months after chemotherapy showed tumor enlargement and increased FDG uptake (SUVmax 10.0) (Fig. 3c) . 2.88!0.47). The SUVmax of the primary lesions categorized as high risk was significantly higher than that of the primary lesions categorized as low and intermediate risk. This observation suggested that the degree of FDG uptake may be a useful indicator of risk category. The size of the recurrent tumor in patient No.14 was small (about 1 cm). FDG uptake depends on spatial resolution of the PET/CT system and a partial volume effect may decrease FDG uptake, which leads to low SUV in a small tumor (6) . Therefore, this recurrent tumor showed relatively low uptake (SUVmax 2.5) in spite of being high-risk.
The patients of GIST post operation showing no abnormal FDG uptake on PET/CT are clinically considered as no recurrence and no metastasis. PET/CT is useful for follow-up examinations of GIST post operation.
In case 2, follow-up PET/CT performed 4 months after chemotherapy showed a reduction in tumor size and lower FDG uptake. Imatinib mesylate was considered to be effective, but follow-up PET/CT performed 10 months after chemotherapy showed tumor enlargement and increased FDG uptake. This was considered to be indicative of resistance to imatinib mesylate (7) . It has been reported that many GISTs may not change significantly in size during early response to imatinib mesylate administration (8) . PET has been shown to be highly sensitive in detecting early response to imatinib mesylate therapy (8, 9) . It has been reported that density reduction on CT reflects necrotic changes in the tumor and is a predictor of early response to imatinib mesylate therapy. However, it is relatively difficult to evaluate early response to imatinib mesylate therapy by CT alone (8, 10) . If a tumor temporarily grew larger as an early response to imatinib mesylate therapy, it might be evaluated as showing a lack of response to imatinib mesylate therapy (10) . By means of PET/CT, we can evaluate response to imatinib mesylate therapy before tumor shrinkage.
It may be that GISTs in pathologically high-risk patients have high glucose metabolism (4). Since 18 F-FDG PET/CT can evaluate glucose metabolism, it may be a useful tool for determining GIST risk category.
